- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.03. | Arvinas gets positive breast cancer data, but finds differentiation a hard sell | ||
| 11.03. | 2seventy bio, Bluebird's cell therapy spinout, sells to Bristol Myers for less than $300M | ||
| 10.03. | Beam base editing therapy gets 'proof of concept' in rare lung disease | ||
| 10.03. | Novo's Wegovy successor disappoints in second large trial | ||
| 10.03. | Mineralys shares climb on study data for blood pressure drug | ||
| 10.03. | SynWeave: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability | ||
| 10.03. | 3 ways to accelerate development and de-risk cell and gene therapy manufacturing | ||
| 07.03. | J&J scraps depression testing for potential blockbuster drug | ||
| 07.03. | Walgreens to be acquired in $10B take-private deal | ||
| 07.03. | Roche launches new Boston center; NIH centralizes peer review | ||
| 07.03. | Nimbus swaps CEOs and turns to new leader for 'next chapter' | ||
| 07.03. | Vertex's new pain drug gets first coverage nod from major insurer | ||
| 06.03. | Following FDA cuts, Trump nominee Makary vows 'independent' staff review | ||
| 06.03. | Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting | ||
| 06.03. | Federal judge extends block on Trump plan to limit NIH payouts | ||
| 06.03. | The top 3 impacts of Trump's health data purge | ||
| 06.03. | Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy | ||
| 06.03. | Tris to ask for approval of dual-acting pain drug | ||
| 05.03. | Jazz expands in oncology with $935M deal for Chimerix | ||
| 05.03. | Bayer braces for 'difficult' year before turnaround pays dividends | ||
| 04.03. | Sofinnova secures €1.2B for new biotech investments | ||
| 04.03. | Neumora bids farewell to R&D head; Biohaven's 'one step forward, one step back' data | ||
| 04.03. | Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda | ||
| 03.03. | Biotech startup pulls in $187M to make 'multi-payload' ADCs | ||
| 03.03. | AbbVie gets into obesity with $350M deal for once-weekly shot |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .